Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 25

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 25
---
 capability, or other transaction terms at that time or since then. Such parties had the ability to make an unsolicited proposal to the Board during the post-signing period but did not submit a competing proposal v v ~13-month opportunity period from initial media reports of takeover interest in STAAR until announcement of acquisition by Alcon; no competing proposals submitted ~14-month period from initial media reports of takeover interest in STAAR until the end of the “window shop” period 31 Aug 5, 2025 Announced acquisition by Alcon with favorable “window shop” provision As set forth in the definitive proxy, two parties approached STAAR via email with vague communications, but neither submitted a competing proposal or took further action to pursue a deal EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

The Alcon merger is not only the best path forward for STAAR stockholders, but will also accelerate ICL adoption by more surgeons and patients STAAR ALCON Sales Force (YE 2024) 215(1) 3,900 Manufacturing footprint 3 17 Cash (Latest Reported Quarter) $190 $1,408 R&D Spend (2024) $54 $876 Sales / Marketing Spend (2024) $108 $2,553(2) “As a significantly larger company, Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology to more surgeons and patients worldwide.” – STAAR CEO $ in millions Source: Company filings. (1) Includes all direct representatives, practice development managers, clinical application specialists and leaders within each region. (2) Based on 2024A reported SG&A spend, allocated based on reported S&M employee headcount as a % of total S&M and G&A employees. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Claims By Broadwood Partners are Flawed and Misleading and Reflect a Misunderstanding of STAAR’s Standalone Challenges, Value, and Potential Buyer Interest in STAAR EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Claims by Broadwood are flawed and misleading and reflect a misunderstanding of STAAR’s standalone challenges, value, and potential buyer interest in STAAR Claims By Broadwood Partners “Deficient